Mylan asks SCOTUS to end NHK-Fintiv rule

Mylan Laboratories has urged the US Supreme Court to overturn the controversial NHK-Fintiv rule, claiming that it is “unlawful”.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Intel backs Mylan's anti-Fintiv SCOTUS stance

16 September 2021 Intel has backed Mylan's bid to convince the US Supreme Court to remove the controversial NHK-Fintiv rule, on the basis that it is “unlawful”.

Americas

Mylan, Edwards back NHK-Fintiv challenge

31 August 2021 Mylan Pharmaceutical and Edwards Lifesciences have joined a petition urging the US Supreme Court to order the US Court of Appeals for the Federal Circuit to reconsider inter partes review petitions that have been denied due to the NHK-Fintiv rule.

Americas

Janssen sues Mylan to block generic of schizophrenia drug

29 September 2020 A Johnson & Johnson company, Janssen Pharmaceuticals, is seeking a court order blocking Mylan from making copies of its schizophrenia treatment, Invega Trinza, until its patent expires in 2036.

More on this story

Americas

Intel backs Mylan's anti-Fintiv SCOTUS stance

16 September 2021 Intel has backed Mylan's bid to convince the US Supreme Court to remove the controversial NHK-Fintiv rule, on the basis that it is “unlawful”.

Americas

Mylan, Edwards back NHK-Fintiv challenge

Americas

Janssen sues Mylan to block generic of schizophrenia drug

More on this story

Americas

Intel backs Mylan's anti-Fintiv SCOTUS stance

16 September 2021 Intel has backed Mylan's bid to convince the US Supreme Court to remove the controversial NHK-Fintiv rule, on the basis that it is “unlawful”.

Americas

Mylan, Edwards back NHK-Fintiv challenge

Americas

Janssen sues Mylan to block generic of schizophrenia drug